Nanomedicine in Hepatocellular Carcinoma: A New Frontier in Targeted Cancer Treatment

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is associated with a dismal median survival of 2–9 months. The fundamental limitations and ineffectiveness of current HCC treatments have led to the development of a vast range of nanotechnologies with the goal of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bakrania, Anita, Zheng, Gang, Bhat, Mamatha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779722/
https://www.ncbi.nlm.nih.gov/pubmed/35056937
http://dx.doi.org/10.3390/pharmaceutics14010041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779722/
https://www.ncbi.nlm.nih.gov/pubmed/35056937
http://dx.doi.org/10.3390/pharmaceutics14010041

Ejemplares similares